Kategoria: Bez kategorii

Local company urges smokers to quit smoking with the Smokerlyzer® for World Cancer Day.

World cancer day takes place every 4th February across the globe and this year the taglines are “A Day to Unite” and “We Can, I Can”, in a bid to show support for all those affected by cancer. The day also aims to increase awareness of cancer and to educate and encourage the world to donate, and help prevent cancer; a disease which claimed the lives of 8.2 million people worldwide in 2012 and is expected to claim up to 13 million by 2030 [1].

Statistics show that lung cancer is the “leading cause of cancer death in men and the second leading cause in women” but unfortunately “smoking is by far the most important risk factor for lung cancer” and the most preventable one (American Cancer Society, 2015) .

 A leading manufacturer of exhaled breath and gas monitoring instruments, who in 2016 are celebrating two important anniversaries – 40 years in business and 30 years of one of their most successful exports – the Smokerlyzer, Bedfont Scientific are revered as pioneers in the medical gas analysis market.

 Jason Smith, General Manager at Bedfont, comments,

“The Smokerlyzer is a breath analysis monitor that detects the harmful amount of carbon monoxide (CO) in your lungs, and therefore your blood, that is inhaled from smoking. Those who smoke can build up high levels of CO in the blood, which can lead to heart disease, circulation problems and high blood pressure. Used in smoking cessation clinics, it is a way to establish a smoker’s status whilst acting as a motivational visual aid to encourage them to quit and to measure their progress whilst doing so, helping to prevent cancer and other smoking related diseases.”

 Jane Wright, Public Health Manager at Warwickshire Stop Smoking Service and long-term advocate of the Smokerlyzer, said,

“The Smokerlyzer CO monitors have been providing support to health professionals and acted as a motivational aid to smokers for the past few decades. Being able to support smokers daily and incorporating stop smoking treatment into their tech-products will massively increase the chance of helping smokers to quit.”

REFERENCES
[1] American Cancer Society. Global Cancer Facts & Figures 3rd Edition. Atlanta: American Cancer Society; 2015

Local Kent company based in Harrietsham – Bedfont Scientific Ltd – has now released its video as part of the campaign to compete for ‘National Public Champion’ in this year’s European Business Awards and they need your votes!

Bedfont Scientific, based in Harrietsham, Kent, has posted a video explaining why you should vote for them on its website at www.bedfont.com, giving a powerful insight into the story of the business and its success. In 2016, the company is celebrating two important anniversaries – 40 years in business and 30 years of one of their most successful exports – the Smokerlyzer.  Revered as pioneers in the breath analysis market, their products are now available, in over 70 countries across the world with an unprecedented network of appointed distributors.

The European Business Awards was created to recognise and promote business success and support the development of a stronger business community throughout Europe. 

Competing against all other country National Champions for the public vote, the company with the most votes will be named ‘National Public Champion’ for the UK on 7th March 2016. The first phase of the online voting is open from 11 January to 26 February 2016. 

Trevor Smith, Managing Director at Bedfont, says:

“We are grateful for the opportunity to show the people of Kent what our business does and how we save lives. We are encouraging people to vote online for us once they have viewed our video. The public vote means a great deal as it’s not just our existing and potential customers giving their approval to our success but also all the people we’ve helped in our 40 years of business.”

Adrian Tripp, CEO of the European Business Awards, said,

“Last year the public vote generated over 170,000 votes from across the world.  It is a very important part of the Awards as it gives these entrepreneurial companies another way of showcasing their achievements.”

Bedfont Scientific Ltd based in Harrietsham, Kent, aims to expand its Gastrolyzer range across the UK and Ireland with the help of new distributor Kebomed.

Bedfont Scientific, a leading manufacturer of exhaled breath monitors, are proud to introduce Kebomed as the new distributor for its Gastrolyzer range throughout the United Kingdom and Ireland. Kebomed will become the 74th member of Bedfont’s exclusive diagnostics distributor network; a structure which has led to much success for Bedfont.

The Gastrolyzer range uses breath analysis to measure levels of Methane, Hydrogen and Oxygen and can accurately detect a range of gastrointestinal (GI) disorders such as Small Intestinal Bacterial Overgrowth (SIBO) or food intolerances such as lactose or fructose intolerance. The Gastrolyzer range is also commonly used in the investigation of Irritable Bowel Syndrome (IBS), a disorder which affects 23 per cent of people worldwide. The success of the Gastrolyzer range is due to the innovative way in which it can help detect GI disorders; its non-invasive manner and instant results are unlike more traditional methods which can take up to two weeks to diagnose.

Matthew Skinner, Gastrolyzer Product Manager at Bedfont, says,

„We always welcome the opportunity to start new collaborations with new distributors; Kebomed have the knowledge of the industry and share our belief in the importance of Gastrointestinal services. We welcome Kebomed into our fold and hope that this new relationship helps us to further strengthen our coverage of the Gastrolyzer range throughout the United Kingdom and Ireland”.

Pardeep Rai, GI Sales Director at Kebomed, says, 

„We aim to use our knowledge of the GI market to increase the Gastrolyzer’s portfolio in the UK and Ireland, and look forward to this opportunity leading to growth for both companies”.  

Bedfont Scientific Limited has created a subsidiary as part of its long term development and expansion plans. The new company NOxBOX Limited will concentrate on its hugely successful range of Inhaled Nitric Oxide monitoring systems.

Bedfont Scientific Limited, established in 1976 in Harrietsham, Kent, specialises in exhaled breath and gas monitors which are used in the medical industry. The NOxBOX range was introduced by Bedfont in 1992 and is used to deliver and monitor inhaled nitric oxide (iNO) therapy.

iNO therapy is mainly used in intensive care units (ICU) to aid in the therapeutic care of premature babies and patients under severe respiratory distress. Using iNO therapy allows the blood supply to pick up oxygen from the lungs more readily by dilating the pulmonary arteries, making it the ideal method of treatment for pulmonary hypertension and other conditions that can lead to severe breathing difficulties. It is also the only iNO therapy monitor that can be used during transport, making it ideal for ambulances.

The new subsidiary company will focus on increasing awareness of the NOxBOX product and associated healthcare benefits to improve market share in the UK, Europe and further develop its customer base across the global market, while its parent company Bedfont Scientific will concentrate on developing new products and increasing use of its wide range of existing breath and gas monitoring systems.

Jason Smith, Bedfont Scientific’s General Manager, says,

“The success of the NOxBOX range has led us to what we feel is a natural progression that will further ensure the continued high levels of quality and service for our customers.

“Our aim for NOxBOX Limited is to grow the customer base globally, continuing to save lives, one breath at a time.”

Giving up smoking is one of the most popular New Year’s Resolutions and every year on January 1, millions of people around the world make themselves a promise to somehow improve their lives or do something they’ve always wanted, but never have. However, while 22 percent of the UK population resolved to quit in January 2015 [1], the average time before they went back to smoking was just 24 days [2].

The new iCO Smokerlyzer is the latest CO monitor from Bedfont Scientific for use in smoking cessation. Through a simple, non-invasive breath test this monitor can measure the harmful levels CO in the blood caused by smoking, acting as a motivational tool to help quit. Statistics from the Health & Social Care Information Centre found that in the UK between April and June 2015, 72 percent of those who quit smoking had their results confirmed through CO verification [3].

A recent study by Grant et al. (2015) looked at CO testing within Stop Smoking Services (SSS). In their findings, one client highlighted that CO monitoring was one of the most useful elements of the SSS he received, „one of the most useful things I found about it was the CO readings every week…you know, you can’t fool a machine, so it’s difficult to fool yourself then” [4].  With CO monitoring already acting as a highly motivational tool, the ability to monitor your CO from a more comfortable environment like your home shows promise for the iCO.

The iCO Smokerlyzer plugs into the headphone slot of your device and is used in conjunction with the Smokerlyzer app. Instant readings can be downloaded to a personal profile, allowing users to track their progress, and be motivated to quit smoking, anytime, anywhere. What’s more, progress can be shared with smoking cessation advisors, fellow quitters, friends and family.

Dominic Finn, Chief Technology Officer at North 51 Healthware, comments,

„The new iCO Smokerlyzer presents a brilliant opportunity for Smoking Cessation Services to work even closer with clients whilst trying to quit smoking. Clients can track their own quit attempts and the data can be pushed to our QuitManager product to help Advisers flag those smokers that need the most support.”

REFERENCES
[1] Supplymanagement.com, (2015). Supply Management | The procurement and supply website. [online] Available at: http://www.supplymanagement.com/blog/2015/01/what-are-the-uks-top-10-new-years-resolutions-for-2015 [Accessed 30 Nov. 2015].
[2] Withnall, A. (2014). Poll reveals 'Fail Friday’ as the day you are most likely to break. [online] The Independent. Available at: http://www.independent.co.uk/news/uk/home-news/poll-reveals-fail-friday-as-the-day-you-are-most-likely-to-break-your-new-years-resolution-9034571.html [Accessed 30 Nov. 2015].
[3] Hscic.gov.uk, (2015). Find data – Health & Social Care Information Centre. [online] Available at: http://www.hscic.gov.uk/catalogue/PUB18749 [Accessed 30 Nov. 2015].
[4] Grant, A., Ashton, K. and Phillips, R. (2015) Foucualt, Surveillance, and Carbon Monoxide Testing within Stop Smoking Services. Qualitative Health Research. Vol.25 (7) 912-922.

Kent-based Bedfont Scientific, has launched UK production of its iCO™ Smokerlyzer® to be shipped worldwide.

Bedfont Scientific Ltd, based in Kent, has been in the business of breath analysis and gas monitoring for almost 40 years now. Their name is well known throughout the medical industry thanks to their high quality breath analysers. They have several products including the Gastrolyzer range, which offers a non-invasive method to diagnose food intolerances and gastrointestinal disorders; the NObreath FENO monitor, which aids in the management & treatment of respiratory diseases, helping to differentiate between respiratory conditions such as asthma and COPD; and the Smokerlyzer range, a carbon monoxide (CO) monitor that is a motivational tool for smoking cessation. Most recently, Bedfont Scientific has launched the iCO™ Smokerlyzer®, the world’s first Smokerlyzer CO monitor for your smartphone or tablet.

Jason Smith, Bedfont’s General Manager, comments,

“We have traditionally manufactured our high volume products in China and thanks to the Manufacturing Advisory Service, this is the first of the range to be built here in Kent.  The iCO Smokerlyzer is proudly designed, manufactured, assembled, packaged and distributed here in Kent. This will undoubtedly provide greater control over quality and supply; bringing benefits to both companies. Bedfont had a forty percent increase in sales turnover in the past two years with seventy-eight percent of turnover being generated from exports. We predict that a homecare breath CO monitor will greatly increase exports, especially since our main target is the USA, which has huge demand for consumer healthcare devices.”

The product launch and UK production is expected to further boost exports to the company’s worldwide range of clients. Bedfont Scientific is a National Champion for Exporting, and an Export Category nominee in the European Business Awards.

Bedfont Scientific, based in Kent, a leading manufacturer of breath testing equipment in the UK releases the latest CO monitor for use with smartphones and tablets, to help people stop smoking.

Quitting smoking has never been easy, but it is a habit that more and more  people are trying to give up, especially with more laws than ever before banning smoking in public places and now in the UK from October 2015 in cars.

Bedfont Scientific Ltd, a pioneer in smoking cessation monitors, has combined the drive to quit smoking with the ever-growing use of technology and applications to create the latest CO monitor that connects to your smartphone or tablet. Bedfont has produced the Smokerlyzer® for 30  years which offers an easy to use hand-held and non-invasive way to test the level of Carbon Monoxide (CO) in a patient’s blood. They recognise that mobile phones and tablets play a significant part in consumers’ lives and wanted to adapt the technology so that CO monitoring could be more accessible to those who do not have the time to consult a specialist, and so iCO was born.

Due to be launched November 2015, the iCO Smokerlyzer is small, sleek and portable. Once you have the app, the monitor is easy to use and instant readings can be downloaded to your personal profile, meaning you can track your progress, and be motivated, anytime, anywhere. Using a monitor to assist with quitting is proven to improve end results.

A study by  Beard and West (2012) on the effectiveness of personal carbon monoxide monitoring, found that out of ten smokers, “seven of the smokers reported that they felt as though the monitors had reduced their cigarette consumption… Six smokers reported a lower nicotine dependency relative to baseline. Over the six weeks there appeared to be a significant decline in the number of cigarettes smoked per day”.

Beard, E. and West, R. (2012). Pilot Study of the Use of Personal Carbon Monoxide Monitoring to Achieve Radical Smoking Reduction. J. Smok Cessat, 7(01), pp.12-17. (Accessed: 19th October 2015).

The iCO offers consumers the opportunity to save money, and take control of their quitting progress, one breath at a time.